The Beat AML master study is currently open at 12 academic sites and has enrolled over 1,600 patients to date. Currently we are focusing our trials in the upfront setting with venetoclax and azacitidine combinations for those mutations that aren't doing well, that need a targeted approach. We also are focusing in newly diagnosed to hit those mutations that don't really have a good treatment such as those with TP53 and complex karyotype.

We also are prioritizing our trial to look in the relapsed/refractory community. This is a new thing for us and we have recently just opened up our first relapsed/refractory study in collaboration with Lamont Therapeutics. This is treating patients who are relapsed/refractory with a FLT3 mutation. We have this open and we're excited to form new collaborations with companies who are looking at patients who are relapsed/refractory AML, and particularly to those who are relapsed/refractory to venetoclax and azacitidine.

Our other priority right now for the Beat AML trial is to work with companies in first in human studies. We see this as a great opportunity to be able to collaborate with companies early on to be able to push promising agents that have a novel method of action or a new novel target to be able to get these into patients sooner to hopefully be able to increase survival for our older AML population.